Course for Interventionist in training 2013

IV Course “Jose Gabay” for Interventional trainees, held on August 6, 2013 in the Hotel Transamerica Auditorium, Sao Paulo, Brazil, as a pre-congress SOLACI -SBHCI activity. –

 

// View Course 2013 order of merit 

More articles by this author

See the Presentations of the 13th ProEducar Fellows Course

  During SOLACI-SBHCI 2023, our traditional education program for young interventionists ProEducar Fellows Course was held.  Discover the presentations of the prestigious interventionists that made part of this 13th edition...

The best images of the 13th ProEducar Fellows Course at SOLACI-SBHCI 2023

Relive the best images of the 13th ProEducar Fellows Course held on August 2 during the SOLACI-SBHCI 2023 Congress in the URCA Room of...

13th ProEducar-SOLACI Fellows Course Held at SOLACI-SBHCI 2023

ProEducar-SOLACI Fellows Course continues to grow! For the thirteenth consecutive year, the traditional SOLACI course for fellow interventionists was held at SOLACI-SBHCI 2023. The course...

Teve lugar o 13º Curso de Fellows do ProEducar-SOLACI no Congresso SOLACI-SBHCI 2023

o Curso de Fellows do ProEducar-SOLACI continua crescendo! Pelo décimo terceiro ano consecutivo teve lugar o tradicional Curso da SOLACI para intervencionistas em formação...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...